1. Increasing prevalence of chronic diseases such as cardiovascular diseases and cancer, which require advanced diagnostic procedures using microbubble/ultrasound contrast agents.
2. Technological advancements in ultrasound imaging and microbubble technology, leading to improved imaging accuracy and efficacy, driving the demand for contrast agents.
3. Growing geriatric population globally, as elderly individuals are more prone to chronic diseases and require regular imaging tests for diagnosis and monitoring.
4. Growing demand for minimally invasive diagnostic procedures, which utilize microbubble/ultrasound contrast agents for better visualization and accurate diagnosis.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Therapeutic Area, Application |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Lantheus Holdings, Bristl-Myers Squibb, Bracco, GE Healthcare, Daiichi Sankyo Company Limited, NanoPET Pharma, Leriva, Koninklijke Philips N.V., Siemens Healthineers AG and others. |
1. High cost associated with microbubble/ultrasound contrast agents, limiting their adoption in developing regions and among low-income individuals.
2. Stringent regulatory guidelines for the approval and commercialization of contrast agents, leading to longer timeframes for product launch and limiting market growth.
3. Limited awareness and education among healthcare professionals and patients about the benefits and applications of microbubble/ultrasound contrast agents, leading to slower adoption and limited market penetration.